Nanjing Red Sun (000525.SZ) stock trading has been subject to delisting risk warning and continues to implement other risk warnings. The stock will be suspended from trading for one day on September 18th.
ST Red Sun (000525.SZ) announced that the Nanjing Intermediate People's Court has accepted the company's restructuring, in accordance with the "Shenzhen Securities..."
Nanjing Red Sun (000525.SZ) announced that due to the ruling of the Nanjing Intermediate People's Court accepting the company's restructuring, in accordance with the Shenzhen Stock Exchange Stock Listing Rules (revised in 2024), the company's stock will be suspended from trading for one day starting on September 18, 2024, and will resume trading starting on September 19, 2024.
According to Rule 9.4.1(9) of the Stock Listing Rules, the company's stock will be subject to "Risk Warning of Delisting" and continue to implement "Other Risk Warnings" starting from the resumption of trading on September 19, 2024. The stock abbreviation will be changed from "Nanjing Red Sun" to "*ST Hongyang", the stock code will remain as "000525", and the daily trading limit for the stock will still be 5%.
Related Articles

William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.
William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.

RECOMMEND





